FDA Approves APRACLONIDINE — Sandoz Inc

# FDA Approves Sandoz's Apraclonidine for Ophthalmic Use Sandoz Inc. received FDA approval for apraclonidine hydrochloride, an ophthalmic treatment that expands the company's portfolio in the eye care market and positions it to capture share in the glaucoma and ocular hypertension segments. The approval of the alpha-2 adrenergic agonist strengthens Sandoz's competitive standing against other pharmaceutical players in the ophthalmology therapeutic area.